Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Nykode Therapeutics ASA
NYKDNykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway. Address: Oslo Research Park, Oslo, Norway, 0349
Analytics
Objectif de Cours de WallStreet
22.77 NOKRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés NYKD
Analyse des dividendes NYKD
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes NYKD
Valorisation des titres NYKD
financières NYKD
Résultats | 2019 | Dynamique |